## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	•	•	,	
heet	1		 of	1

Approved for use till	ough 03/3 1/2003, Olvid 0031-0031
Application Number	10/563,498
Filing Date	June 7, 2006
First Named Inventor	Ansorge, et al.
Group Art Unit	1654
Examiner Name	Ha, Julie
Attorney Docket Number	013183.00055

Examiner Initials* Cite		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
19 2008	1	RIEMANN, et al.; Stimulation of the expression and the enzyme activity of aminopeptidase N/CDE13 and dipetidylpeptidase IV/CD27 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13; Clin Exp Immunol 1995, Vol. 100; pages 277-283.		
THADEMAR	/			
THAU		•		
<u> </u>	,			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Examiner

Signature

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Translation is attached.